HLS Therapeutics Inc
- LAST PRICE4.6500
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.7800/ 15
- Ask / Lots4.7800/ 6
- Open / Previous Close0.0000 / 4.6500
- Day Range---
- 52 Week Range
- Volume8
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Apr 25, 2024
HLS Therapeutics to Host Q1 Fiscal 2024 Financial Results Conference Call, from 8:50AM ET on Thursday Apr 25, 2024 by Dow Jones
8:50AM ET on Thursday Apr 25, 2024 by Dow JonesPress Release: HLS Therapeutics to Host Q1 Fiscal 2024 Financial Results Conference Call, from 8:50AM ET on Thursday Apr 25, 2024 by Dow Jones
8:50AM ET on Thursday Apr 25, 2024 by Dow Jones
Apr 9, 2024
HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference, from 6:30AM ET on Tuesday Apr 09, 2024 by Dow Jones
6:30AM ET on Tuesday Apr 09, 2024 by Dow Jones
Apr 8, 2024
New REDUCE-IT Analyses Show VASCEPA (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups, from 6:30AM ET on Monday Apr 08, 2024 by Dow Jones
6:30AM ET on Monday Apr 08, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
HLS Therapeutics Inc | 148.3M | -4.0x | --- |
Company Information
HLS Therapeutics Inc. is a pharmaceutical company. It is focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Insite, MyCare Psychiatry, PERSERIS, Trinomia and Vascepa. Its lead product is Clozaril, which is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Trinomia product related to the treatment of cardiovascular disease.
Contact Information
- Headquarters
- 10 Carlson Court, Suite 701ETOBICOKE, ON, Canada M9W 6L2
- Phone
- 647-495-9000
- Fax
- 647-495-9000
Executives
- Chairman of the Board
- Greg Gubitz
- Chief Executive Officer, Director
- Craig Millian
- Chief Financial Officer
- Tim Hendrickson
- Senior Vice President - Human Resources, Legal and Compliance, Company Secretary
- Ryan Lennox
- Vice President, Controller
- David Spence
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $148.3M |
|---|---|
Revenue (TTM) | $86.2M |
Shares Outstanding | 31.9M |
HLS Therapeutics Inc does not pay a dividend. | |
Beta | 1.11 |
EPS | $-1.17 |
Book Value | $4.18 |
P/E Ratio | -4.0x |
Price/Sales (TTM) | 1.7 |
Price/Cash Flow (TTM) | 24.6x |
Operating Margin | -44.08% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
